

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 117-473


C# M#

ARTHUR, M. et al.

Serial No. 10/650,074

Filed: August 28, 2003

Title: TREATMENT FOR LIVER DISEASE



C/A.U.

Examiner:

Date: July 7, 2005

JRW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

 Correspondence Address Indication Form Attached.**Fees are attached as calculated below:**

| | | | | | | |
|--|----|-----------------|---|----------------------|-----------------------------|----|
| Total effective claims after amendment previously paid for | 20 | (at least 20) = | 0 | minus highest number | \$0.00 (1202)/\$0.00 (2202) | \$ |
| Independent claims after amendment previously paid for | 3 | (at least 3) = | 0 | minus highest number | \$0.00 (1201)/\$0.00 (2201) | \$ |

If proper multiple dependent claims now added for first time, (ignore improper); add
\$360.00 (1051)/\$180.00 (2051) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s)

| | |
|------------------------|-------------------------------------|
| One Month Extension | \$120.00 (1251)/\$60.00 (2251) |
| Two Month Extensions | \$450.00 (1252)/\$225.00 (2252) |
| Three Month Extensions | \$1020.00 (1253)/\$510.00 (2253) |
| Four Month Extensions | \$1590.00 (1254)/\$795.00 (2254) \$ |

Terminal disclaimer enclosed, add
\$130.00 (1814)/ \$65.00 (2814) \$

Applicant claims "small entity" status. Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee
\$180.00 (1806) \$

Assignment Recording Fee
\$40.00 (8021) \$

Other:
\$

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor
Arlington, Virginia 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

ARTHUR, M. et al.

Serial No. 10/650,074

Filed: August 28, 2003

For: TREATMENT FOR LIVER DISEASE



Confirmation No. 7212

Atty. Ref.: 117-473

Group:

Examiner:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

July 7, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits] **N/C**

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] **N/C**

2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] **\$180.00**

3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies (as may be required) of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

ARTHUR, M. et al.
Serial N^o. 10/650,074
July 7, 2005

This paper is submitted in accordance with:

- 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - a) The required Statement made in item 8 below; or
 - b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - b) The required Statement is stated in item 8 below.
- 8. Statement under 37 CFR 1.97(e)
 - a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

ARTHUR, M. et al.
Serial No. 10/650,074
July 7, 2005

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

| | | |
|--|-------------------|------------|
| INFORMATION DISCLOSURE CITATION | ATTY. DOCKET NO. | SERIAL NO. |
| | 117-473 | 10/650,074 |
| | APPLICANT | |
| | ARTHUR, M. et al. | |
| (Use several sheets if necessary) | FILING DATE | GROUP |

JUL 07 2005

PATENT & TRADEMARK OFFICE 592

(Use several sheets if necessary)

FILING DATE

SERIAL NO.

10/650,074

ARTHUR, M. et al.

FILING DATE

GROUP

August 28, 2003

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

TRANSLATION

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|--|--|
| | Ruddell et al, "Expression and Function of 5-Hydroxytryptamine 2 Receptors on the Surface of Rat Hepatic Stellate Cells", <i>Hepatology</i> 36(4):391 Part 2 Suppl. (2002) – AASLD Abstracts |
| | Oakley et al, "Sulfasalazine Inhibits NFKB Activity and Induces Apoptosis of Rat Hepatic Stellate Cells", <i>Hepatology</i> 36(4):1291 Part 2 Suppl. (2002) – AASLD Abstracts |
| | Mann et al, "The NFKB Inhibitor Sulfasalazine Enhances Recovery from CCL4 Induced Fibrosis: Therapeutic Implications", <i>Hepatology</i> 38(4):896 Suppl. 1 (2003) – AASLD Abstracts |
| | Oakley et al, "The Inhibitory I κ BKINASE (IKK) Inhibitor Sulfasalazine Inhibits NF κ B Activation and Induces Apoptosis in Activated Rat Hepatic Stellate Cells (HSC)", <i>GUT</i> 52(5):23 (2003) – BASL Abstracts |
| | Oakley et al, "Hepatocytes Express Nerve Growth Factor during Liver Injury", <i>American Journal of Pathology</i> 163(5):1849-1858 (2003) |
| | Ruddell et al, "Expression and Function of 5-Hydroxytryptamine ₂ Receptors on the Surface of Rat Hepatic Stellate Cells", <i>GUT</i> 52(2):32 (2003) – BASL Abstracts |
| | |
| | |
| | |
| | |
| | |

***Examiner**

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)